Successful Treatment of Severe Psoriasis Relapse With Secukinumab(IL17 a Inhibitor) After Abrupt Brodalumab (IL17 Receptor Inhibitor) Discontinuation: A Retrospective Study Evaluating Long Term Efficacy and Safety

Journal of the American Academy of Dermatology - United States

doi 10.1016/j.jaad.2018.03.027